Vaccinex Inc VCNX:NASDAQ

Earnings Announcement Next Earnings date is expected on 08/15/2022
Last Price$1.13Cboe Real-Time Last Sale as of 3:41PM ET 8/10/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.07(6.60%)
Bid (Size)$1.09 (100)
Ask (Size)$1.14 (6,900)
Day Low / High$1.01 - 1.15
Volume259.8 K

View Biotechnology IndustryPeer Comparison as of 08/10/2022


Vaccinex Inc ( NASDAQ )

Price: $1.13
Change: +0.07 (6.60%)
Volume: 259.8 K
3:41PM ET 8/10/2022

DiaMedica Therapeutics Inc ( NASDAQ )

Price: $1.70
Change: +0.02 (1.19%)
Volume: 64.2 K
2:14PM ET 8/10/2022


Price: $1.05
Change: +0.04 (3.96%)
Volume: 258.3 K
3:50PM ET 8/10/2022

Cidara Therapeutics Inc ( NASDAQ )

Price: $0.66
Change: +0.03 (5.58%)
Volume: 442.7 K
3:44PM ET 8/10/2022

Alimera Sciences Inc ( NASDAQ )

Price: $7.10
Change: +0.32 (4.72%)
Volume: 31.9 K
11:21AM ET 8/10/2022

Read more news Recent News

Insider Buy: Vaccinex
6:28AM ET 2/01/2022 MT Newswires

Maurice Zauderer, Director, President and CEO, on January 27, 2022, executed a purchase for 1,801,801 shares in Vaccinex (VCNX) for $1,999,999. Following...

Vaccinex Says Two Patients Showed Complete Response in Study of Combo Drug Treatment for Head and Neck Cancer
9:13AM ET 1/26/2022 MT Newswires

Vaccinex (VCNX) said Wednesday that two out of three patients enrolled in a phase 1b study of a combination drug treatment for recurrent or metastatic head...

Vaccinex Reports Positive Interim Data From Study of Pepinemab, Keytruda Combination to Treat Head, Neck Cancer
9:24AM ET 1/04/2022 MT Newswires

Vaccinex (VCNX) reported positive interim safety data from a study of the combination of its lead drug candidate pepinemab and Merck, Inc.'s (MRK) Keytruda...

-- Earnings Flash (VCNX) VACCINEX Reports Q3 Revenue $50,000
8:20AM ET 11/08/2021 MT Newswires


View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionVaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY. View company web site for more details
Address1895 Mount Hope Avenue
Rochester, New York 14620
Number of Employees44
Recent SEC Filing08/08/20228-K
President, Chief Executive Officer & DirectorMaurice Zauderer
Chief Operating OfficerElizabeth Evans
Chief Financial & Accounting OfficerScott E. Royer
Chief Scientific Officer & Senior VP-ResearchErnie Smith

Company Highlights

Price Open$1.03
Previous Close$1.06
52 Week Range$0.90 - 2.59
Market Capitalization$48.2 M
Shares Outstanding42.7 M
SectorHealth Technology
Next Earnings Announcement08/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.67
Beta vs. S&P 500N/A
Revenue$724.0 K
Net Profit Margin-40,802.00%
Return on Equity-155.64%

Analyst Ratings as of 07/08/2021

Consensus RecommendationConsensus Icon
Powered by Factset